JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

825.6 -0.23

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

811.6

Max

827.5

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9B

5.7B

Verkoop

2.8B

16B

K/W

Sectorgemiddelde

52.36

37.461

EPS

6.31

Dividendrendement

0.7

Winstmarge

36.384

Werknemers

47,000

EBITDA

3.3B

7.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+10.05% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.70%

2.33%

Volgende Winsten

30 okt 2025

Volgende dividenddatum

10 dec 2025

Volgende Ex Dividend datum

14 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

35B

725B

Vorige openingsprijs

825.83

Vorige sluitingsprijs

825.6

Nieuwssentiment

By Acuity

52%

48%

295 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 13:04 UTC

Acquisities, Fusies, Overnames

Eli Lilly Agrees to Acquire Adverum Biotechnologies

23 sep 2025, 03:10 UTC

Acquisities, Fusies, Overnames

South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility

25 aug 2025, 15:59 UTC

Belangrijke Marktbewegers

Immuneering Shares Climb On Supply Agreement with Eli Lilly

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 okt 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

17 okt 2025, 15:56 UTC

Winsten

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 okt 2025, 13:53 UTC

Winsten

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 okt 2025, 13:04 UTC

Winsten

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, and More -- Barrons.com

17 okt 2025, 11:19 UTC

Winsten

These Stocks Are Moving the Most Today: Zions Bancorp, Amex, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, AST SpaceMobile, and More -- Barrons.com

17 okt 2025, 10:50 UTC

Winsten

These Stocks Are Moving the Most Today: Zions Bancorp, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, AST SpaceMobile, Amex, and More -- Barrons.com

26 sep 2025, 13:55 UTC

Winsten

These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More -- Barrons.com

26 sep 2025, 09:41 UTC

Winsten

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More -- Barrons.com

23 sep 2025, 02:55 UTC

Acquisities, Fusies, Overnames

South Korea's Celltrion Plans to Invest $1B to Acquire, Expand U.S. Facility

23 sep 2025, 01:27 UTC

Acquisities, Fusies, Overnames

Celltrion: Investment Aims to Remove U.S. Tariff Risks

23 sep 2025, 01:26 UTC

Acquisities, Fusies, Overnames

Celltrion: To Invest Extra KRW700B to Expand Facility in Branchburg, New Jersey

23 sep 2025, 01:26 UTC

Acquisities, Fusies, Overnames

Celltrion: To Spend KRW700B for Acquisition, Initial Operating Costs

23 sep 2025, 01:25 UTC

Acquisities, Fusies, Overnames

Celltrion to Buy Biologics Facility in U.S. for $330M From Eli Lilly

22 sep 2025, 13:43 UTC

Acquisities, Fusies, Overnames

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

26 aug 2025, 13:57 UTC

Winsten

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26 aug 2025, 11:37 UTC

Winsten

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12 aug 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 aug 2025, 19:34 UTC

Marktinformatie

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 aug 2025, 05:32 UTC

Marktinformatie

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 aug 2025, 16:20 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 aug 2025, 14:18 UTC

Marktinformatie
Winsten

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 aug 2025, 13:54 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 aug 2025, 12:12 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 aug 2025, 11:58 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

10.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 909.44 USD  10.05%

Hoogste 1,190 USD

Laagste 700 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

18

Buy

4

Hold

0

Sell

Technische score

By Trading Central

N/A / 884.54Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

295 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat